A scientist pipetting coloured samples into test tubes in a laboratory

PNB Vesper Life Science, Kochi

Developing New Chemical Entities for Unmet and Serious Medical Needs

PNB-001Phase 3 application submitted

Ulcerative Colitis and Crohn's Disease

  • Phase II clinical trials completed for both indications with significant results.
  • Phase III clinical trial application for Ulcerative Colitis submitted to DCGI.
View the indication

01 / 07

Vision

To become a recognized research-driven biopharmaceutical organization dedicated to discovering innovative medicines for serious diseases and unmet medical needs.

Mission

To identify, investigate, and advance novel drug candidates through focused research, scientific collaboration, and systematic evaluation, with the long-term goal of contributing to meaningful improvements in patient care.

A technician among DNA sequencing machines in a genomics laboratory

Research is at the core of the company

Established in India in 2011, PNB Vesper operates through a semi-virtual research model, combining a focused core team with a network of partners across India, the United Kingdom, the United States, Germany, and Thailand to advance drug discovery from molecule synthesis through clinical trials. The company has also recently entered into three agreements with the U.S. Government, through the National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA), to test and develop molecules for Addiction-Related Disorders.

Read the company story

From hundreds of molecules to six leads

  1. DiscoverySystematic molecule synthesis and characterization form the foundation of the pipeline.
  2. SelectionPromising molecules are evaluated and advanced according to their therapeutic potential.
  3. SixPatented NCEs: 2 in Clinical Stage and 4 in Pre-Clinical Stage.

A simplified representation of PNB Vesper's discovery-to-development approach.

1 Platform
4 Therapeutic Areas
14 Indications

6 molecules cover oncology, immune and inflammatory disease, metabolic disease, and CNS and addiction

Select a molecule to see the indications it is being developed for

All 14 molecule–indication links are shown.

Where each molecule stands

The most advanced programme for each molecule, from the pipeline. The full pipeline lists 14 molecule–indication programmes

  • PNB-001
  • PNB-028
  • PNB-081
  • PNB-101
  • PNB-291
  • PNB-091
Graph of the stage of development of each molecule. Horizontal axis: clinical development stage. Vertical axis: molecule. Each marker opens the molecule's lead indications, stage and status.
See the full pipeline and molecule profiles

Evidence From The Clinical Trials

PNB-001, our lead molecule, is Phase 3-ready for Ulcerative Colitis, Phase 2-ready for Type 2 Diabetes, and has advanced to Phase 3 clinical development for COVID-19

Phase 2 studies completed
2

COVID-19 Lung Inflammation
Ulcerative Colitis
Crohn's Disease

Phase 1/2a trial ongoing
1

Pancreatic Cancer
Colon Cancer

PNB-001 · Phase 2 · Ulcerative Colitis

Patients responding after 28 days, as an add-on to mesalamine

Responders on the UC Disease Activity Index after 28 days, by treatment arm
Treatment armPatients responding
Mesalamine alone 4 of 9 (44%)
Mesalamine + PNB-001 50 mg 5 of 9 (55%)
Mesalamine + PNB-001 100 mg 8 of 9 (89%)

The CCK receptor platform

Every PNB Vesper molecule comes from one platform, developed for more than a decade around cholecystokinin (CCK) receptors. Each is designed for a receptor subtype, CCK-A, CCK-B/gastrin or CCK-C, or to block several at once. That is how one chemistry reaches cancer, inflammation, metabolism and the brain

Explore the science
How CCK receptors interact with the opioid system CCK acts on the CCK2 and CCK1 receptors. CCK2 acts on the mu opioid receptor and inhibits the enkephalins; CCK1 stimulates the enkephalins. The enkephalins act on the mu receptor, which leads to analgesia, and on the delta receptor, which leads to behavioral responses. A negative loop links CCK and the mu receptor; the delta receptor feeds back positively on CCK. Illustrative only; not PNB Vesper research data. CCK CCK2(Receptor) CCK1(Receptor) Enkephalins μ δ Analgesia Behavioralresponses
Textbook schematic of a G-protein-coupled receptor. Illustrative, not PNB Vesper data

Mission 2035

To position India as a global powerhouse in discovering and developing novel, safe, and effective New Chemical Entities (NCEs) that transform the treatment of serious diseases and address critical unmet medical needs.

Nine values. One name.

Read the first letters of PNB Vesper's nine core values in order and they spell the company's name.

Passionate

About our commitment to provide breakthrough therapy.

Nurture

A positive global environment, setting a model for others to follow.

Breakthrough

Technology that will lead to better drugs and therapeutics.

Value

Our customers (patients) and stakeholders with utmost respect.

Excellence

In quality and in everything we do.

Seek

New areas to innovate and grow.

Profitable

And sustainable growth.

Ethics

In every step of our way.

Respect

Our partners and associates.

Partner with PNB Vesper

For clinical collaboration, licensing, co-development, investment or media enquiries, the team welcomes the conversation.

info@pnbvesper.com +91 98476 22342 Send an enquiry